Your Messages Inbox
Your Article Summary
See Latest ArticlesAngiotechs Corporate Partner, Boston Scientific, Reports Two-Year SYNTAX Data Showing Comparable Safety Outcomes for Complex Patients Treated with TAXUS Express Stents and Bypass Surgery
Angiotech Pharmaceuticals, 09/03/09
Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific, has reported two–year data from its SYNTAX clinical trial comparing percutaneous coronary interventionusing the Taxus Express Paclitaxel–Eluting Coronary Stent System to coronary artery bypass graft surgery. The overall results demonstrated no statistically significant difference between PCI and CABG in the composite safety endpoint. Boston Scientific made the announcement at the annual European Society of Cardiology Congress in Barcelona.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
Sanofi-aventis, 12/04/09
Watson Receives FTC Clearance for Arrow Acquisition
Watson Pharmaceuticals, 12/03/09
Article Search
Sponsor